Matches in DBpedia 2014 for { ?s ?p Oxford BioMedica (LSE: OXB) is a biopharmaceutical company specialising in the development and commercialisation of innovative gene-based medicines. It was established in 1995 as a spin out from Oxford University. The lead product is TroVax, a therapeutic cancer vaccine for multiple solid cancers, which is in Phase III development incollaboration with Sanofi-Aventis. TroVax failed in a key kidney cancer test in 2008 which caused a dramatic drop in Oxford BioMedica's share priceThe Company’s advanced development pipeline includes treatments for cancer, Parkinson's disease and retinopathy. The company's early stage development pipeline includes preclinical candidates for Stargardt disease, motor neuron disease, spinal muscular atrophy and AIDS.. }
Showing items 1 to 1 of
1
with 100 items per page.
- Oxford_BioMedica abstract "Oxford BioMedica (LSE: OXB) is a biopharmaceutical company specialising in the development and commercialisation of innovative gene-based medicines. It was established in 1995 as a spin out from Oxford University. The lead product is TroVax, a therapeutic cancer vaccine for multiple solid cancers, which is in Phase III development incollaboration with Sanofi-Aventis. TroVax failed in a key kidney cancer test in 2008 which caused a dramatic drop in Oxford BioMedica's share priceThe Company’s advanced development pipeline includes treatments for cancer, Parkinson's disease and retinopathy. The company's early stage development pipeline includes preclinical candidates for Stargardt disease, motor neuron disease, spinal muscular atrophy and AIDS.".